Terns Pharmaceuticals Inc (TERN) Stock Price, Quote & News

Company Profile

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced metabolic stability and liver distribution that is in Phas...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 525 5535

Fax: 650 275 4254

Website: www.ternspharma.com

Address:

1065 East Hillsdale Boulevard, Suite 100, Foster City, United States

shopno Jun. 30 at 12:16 AM

$SLS +1. everyone should check $TERN fabulous 2,600% ride from $2 to $53 just in 1 year! TERN is very relevant, as it's for CML and got acquired for $6.7B with early stage data. BO premium was almost absent telling everyone that it's NOT WISE to get late on-board, if you look for big reward at BO. Some of my calls, for example, are > 10x just within a few months! Check the historical $TERN price here -- on 4/8/2025 price was $2.05, and on 3/30/2026 price was $52.88! $SLS to meet & possibly beat it with blowout GPS readout! https://www.macrotrends.net/stocks/charts/TERN/terns-pharmaceuticals/stock-price-history

0 · Reply

BioRich Jun. 16 at 9:11 PM

$CRMD Quick look over at the gainers for today and I saw this grouping. How many Buyouts or deals did we have in this group? Good lord. Will $CRMD be added to that distinguished list? I think so. For fun, the 2 picks above the screen grab was $AKRO, one below was $NUVL. $TERN? $VRNA? Some real life changes in here. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!

1 · Reply

BIOTECH_GURU Jun. 16 at 1:16 PM

$SLS blah blah blah. Bears came out agains $CAPR at $7.X Came out against $REPL at $3.X Came out agains $TERN at $7.X The science will dictate where we go with $SLS. The harder they short the bigger the potential to launch 10-20x

1 · Reply

BIOTECH_GURU Jun. 9 at 4:06 AM

$ALMS $TERN $GPCR smart people follow the money.

0 · Reply

amessagefromtheodd May. 30 at 11:02 AM

$ALMS $CAPR $SLS $TERN There is more to see 💎 🙌🏿

1 · Reply

Sihtegroftnod May. 30 at 12:58 AM

$ALMS $CAPR $SLS $TERN This! Right here!!

0 · Reply

BIOTECH_GURU May. 30 at 12:48 AM

$SLS they want the retail to sell. They dropped prices for multiple recent biotechs right before the rip. $TERN $CAPR $ALMS Hold the line or regret being Mcpaperhands.

0 · Reply

YouVSYou May. 26 at 1:46 AM

Eli Lilly’s one-time gene editing therapy cut LDL cholesterol by 62% in Phase 1 trial participants, with effects lasting up to 18 months. No serious adverse events reported. $LLY $NVO $HIMS $TERN

0 · Reply

MilsLearning May. 22 at 9:37 AM

$TERN

0 · Reply

BIOTECH_GURU May. 20 at 1:49 PM

$SLS $CAPR $TERN $ALMS $SLS paperhands should be ashamed of selling this anywhere less than $20

1 · Reply

Merck Completes Acquisition of Terns Pharmaceuticals, Inc.

MRK

Apr 27, 2026, 8:05 AM EDT - 2 months ago

Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid Leukemia

Apr 24, 2026, 6:45 AM EDT - 2 months ago

Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.

MRK

Apr 15, 2026, 7:59 AM EDT - 2 months ago

Are TERN, SLNO, WSR Obtaining Fair Deals for their Shareholders?

SLNO WSR

Apr 7, 2026, 9:00 AM EDT - 3 months ago

Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.

MRK

Apr 2, 2026, 4:05 PM EDT - 3 months ago

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

Mar 30, 2026, 7:00 AM EDT - 3 months ago

Terns Pharmaceuticals Annual report: Q4 2025

Mar 25, 2026, 8:00 AM EDT - 3 months ago

Terns Pharmaceuticals Transcript: M&A announcement

Mar 25, 2026, 8:00 AM EDT - 3 months ago

Terns Pharmaceuticals Slides: M&A announcement

Mar 25, 2026, 8:00 AM EDT - 3 months ago

Terns Pharmaceuticals Press release: M&A announcement

Mar 25, 2026, 7:14 AM EDT - 3 months ago

Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline

MRK

Mar 25, 2026, 6:51 AM EDT - 3 months ago

Merck boosts cancer portfolio with $6.7 billion buyout of Terns Pharma

MRK

Mar 25, 2026, 6:49 AM EDT - 3 months ago

Merck Reaches Nearly $6 Billion Deal for Cancer Biotech Terns

MRK

Mar 25, 2026, 6:48 AM EDT - 3 months ago

Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)

MRK

Mar 24, 2026, 9:14 PM EDT - 3 months ago

Merck nears $6 billion all-cash deal to buy Terns Pharma, FT reports

MRK

Mar 11, 2026, 9:00 AM EDT - 4 months ago

Terns Pharmaceuticals Transcript: The Citizens Life Sciences Conference 2026

Mar 9, 2026, 1:40 PM EDT - 4 months ago

Terns Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Mar 2, 2026, 3:50 PM EST - 4 months ago

Terns Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 4:05 PM EST - 4 months ago

Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences

Jan 22, 2026, 10:26 AM EST - 5 months ago

These 20 stocks are strong choices for momentum investors

BE CELC COGT FBYD FRGE INBX KOD

Jan 12, 2026, 6:45 PM EST - 6 months ago

Terns Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 6:45 PM EST - 6 months ago

Terns Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:00 AM EST - 6 months ago

Terns Pharmaceuticals Slides: Corporate presentation

Jan 7, 2026, 4:05 PM EST - 6 months ago

Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference

Dec 15, 2025, 6:31 PM EST - 7 months ago

Terns CEO Amy Burroughs talks cancer drug trial win

Dec 11, 2025, 4:05 PM EST - 7 months ago

Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Dec 9, 2025, 11:30 PM EST - 7 months ago

Terns Announces Pricing of Upsized $650 Million Public Offering

Dec 9, 2025, 3:31 PM EST - 7 months ago

Cancer Study Buoys These Small Biotechs

ACLX LEGN

Dec 9, 2025, 6:12 AM EST - 7 months ago

Terns Announces Proposed Public Offering

Dec 8, 2025, 4:30 PM EST - 7 months ago

Terns Pharmaceuticals Transcript: Study Update

Dec 8, 2025, 4:30 PM EST - 7 months ago

Terns Pharmaceuticals Press release: Study Update

Dec 8, 2025, 4:30 PM EST - 7 months ago

Terns Pharmaceuticals Slides: Study Update

$Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701's Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting$

Dec 8, 2025, 2:45 PM EST - 7 months ago

Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701's Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting

Nov 17, 2025, 11:30 AM EST - 8 months ago

Terns Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Nov 14, 2025, 4:05 PM EST - 8 months ago

Terns Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London

Nov 10, 2025, 4:05 PM EST - 8 months ago

Terns Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Nov 10, 2025, 4:00 PM EST - 8 months ago

Terns Pharmaceuticals Quarterly report: Q3 2025

Nov 10, 2025, 4:00 PM EST - 8 months ago

Terns Pharmaceuticals Earnings release: Q3 2025

$Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting$

Nov 3, 2025, 9:05 AM EST - 8 months ago

Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting

Oct 21, 2025, 4:56 PM EDT - 9 months ago

Terns Pharma ends obesity drug program after mid-stage trial data

Oct 21, 2025, 4:05 PM EDT - 9 months ago

Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in Obesity

Sep 3, 2025, 4:30 PM EDT - 10 months ago

Terns Pharmaceuticals Transcript: Study Update

Sep 3, 2025, 4:30 PM EDT - 10 months ago

Terns Pharmaceuticals Slides: Study Update

Aug 21, 2025, 4:05 PM EDT - 11 months ago

Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025

Aug 5, 2025, 4:05 PM EDT - 11 months ago

Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Aug 5, 2025, 4:00 PM EDT - 11 months ago

Terns Pharmaceuticals Quarterly report: Q2 2025

Aug 5, 2025, 4:00 PM EDT - 11 months ago

Terns Pharmaceuticals Earnings release: Q2 2025

Jun 23, 2025, 4:07 PM EDT - 1 year ago

Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions

Jun 9, 2025, 4:00 PM EDT - 1 year ago

Terns Pharmaceuticals Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 6, 2025, 7:00 AM EDT - 1 year ago

Terns Pharmaceuticals Slides: Corporate Presentation

Jun 5, 2025, 11:05 AM EDT - 1 year ago

Terns Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

May 29, 2025, 4:05 PM EDT - 1 year ago

Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences

May 14, 2025, 9:30 AM EDT - 1 year ago

Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701

May 8, 2025, 4:05 PM EDT - 1 year ago

Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 8, 2025, 4:00 PM EDT - 1 year ago

Terns Pharmaceuticals Earnings release: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Terns Pharmaceuticals Quarterly report: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Terns Pharmaceuticals Registration statement: Registration Filing

May 7, 2025, 2:30 PM EDT - 1 year ago

Terns Pharmaceuticals Transcript: The Citizens JMP Life Sciences Conference 2025

Apr 30, 2025, 4:05 PM EDT - 1 year ago

Terns Pharmaceuticals to Participate in The Citizens Life Sciences Conference

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Terns Pharmaceuticals Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Terns Pharmaceuticals Proxy statement: Proxy Filing

Apr 2, 2025, 4:05 PM EDT - 1 year ago

Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)

Mar 20, 2025, 4:05 PM EDT - 1 year ago

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

Mar 20, 2025, 4:00 PM EDT - 1 year ago

Terns Pharmaceuticals Earnings release: Q4 2024

Mar 20, 2025, 4:00 PM EDT - 1 year ago

Terns Pharmaceuticals Annual report: Q4 2024

Mar 4, 2025, 2:30 PM EST - 1 year ago

Terns Pharmaceuticals Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 26, 2025, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4)

Feb 25, 2025, 8:05 AM EST - 1 year ago

Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference

Feb 24, 2025, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer

Feb 20, 2025, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors

Feb 12, 2025, 4:00 PM EST - 1 year ago

Terns Pharmaceuticals Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 5, 2025, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 3, 2025, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

Jan 15, 2025, 7:30 PM EST - 1 year ago

Terns Pharmaceuticals Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

Terns Pharmaceuticals Slides: FY 2025

Jan 8, 2025, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 4, 2024, 1:18 PM EST - 1 year ago

Terns's stock soars as analysts cheer leukemia data — and predict more gains

Dec 3, 2024, 8:01 AM EST - 1 year ago

Terns Pharma broadens beyond obesity drugs with upbeat data in leukemia trial

Dec 3, 2024, 8:00 AM EST - 1 year ago

Terns Pharmaceuticals Transcript: Study Result

Dec 3, 2024, 8:00 AM EST - 1 year ago

Terns Pharmaceuticals Press release: Study Result

Dec 3, 2024, 8:00 AM EST - 1 year ago

Terns Pharmaceuticals Slides: Study Result

Nov 19, 2024, 12:00 PM EST - 1 year ago

Terns Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2024

Nov 18, 2024, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors

Nov 15, 2024, 11:19 AM EST - 1 year ago

RFK Jr. is not a fan of weight-loss drugs or vaccines. Stocks are tanking.

AMGN LLY NVO VKTX

Nov 13, 2024, 11:45 AM EST - 1 year ago

Terns Pharmaceuticals Transcript: UBS Global Healthcare Conference 2024

Nov 12, 2024, 9:30 AM EST - 1 year ago

Terns Pharmaceuticals Quarterly report: Q3 2024

Nov 12, 2024, 9:30 AM EST - 1 year ago

Terns Pharmaceuticals Earnings release: Q3 2024

Sep 12, 2024, 7:00 PM EDT - 1 year ago

Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

shopno Jun. 30 at 12:16 AM

0 · Reply

BioRich Jun. 16 at 9:11 PM

1 · Reply

BIOTECH_GURU Jun. 16 at 1:16 PM

1 · Reply

BIOTECH_GURU Jun. 9 at 4:06 AM

$ALMS $TERN $GPCR smart people follow the money.

0 · Reply

amessagefromtheodd May. 30 at 11:02 AM

$ALMS $CAPR $SLS $TERN There is more to see 💎 🙌🏿

1 · Reply

Sihtegroftnod May. 30 at 12:58 AM

$ALMS $CAPR $SLS $TERN This! Right here!!

0 · Reply

BIOTECH_GURU May. 30 at 12:48 AM

$SLS they want the retail to sell. They dropped prices for multiple recent biotechs right before the rip. $TERN $CAPR $ALMS Hold the line or regret being Mcpaperhands.

0 · Reply

YouVSYou May. 26 at 1:46 AM

Eli Lilly’s one-time gene editing therapy cut LDL cholesterol by 62% in Phase 1 trial participants, with effects lasting up to 18 months. No serious adverse events reported. $LLY $NVO $HIMS $TERN

0 · Reply

MilsLearning May. 22 at 9:37 AM

$TERN

0 · Reply

BIOTECH_GURU May. 20 at 1:49 PM

$SLS $CAPR $TERN $ALMS $SLS paperhands should be ashamed of selling this anywhere less than $20

1 · Reply

55X_ROI_Q1_2026 May. 15 at 5:29 PM

$SLS - pardon me @Maxamillion5000, i know some are just getting to know... and for anyone interested in MONEY. https://www.reddit.com/r/sellasLifescience/search/?q=aml-mr&cId=057d1aab-2b7d-4bf0-a2d4-c3227af101f8&iId=8d5110f2-0189-40ea-bc04-b363b5cad724 - link for 009 DD. SLS009 is the only Effective Agent for the Most Dire AML Prognosis, AML-MR - Mutations TP53 Asxl1 Runx Ezh2 -- AML that is mutated, often after Chemo from other cancers. SLS009 has direct market Comps $TERN $FTSV both bought for $5B+ based on Lesser PH2B DATA SLS009 Published at ASH.

0 · Reply

judgeyoung2 May. 5 at 5:10 PM

$GEV sold this right after the spin off. sold $TERN at $7 lmao. i just need to not touch things.

1 · Reply

Floridaorange May. 4 at 3:45 PM

$RXRX notice the yearly chart looks like every beatdown SaaS stock? That’s because the market is not accurately valuing or categorizing $RXRX. Miscategorized = mispriced. Earnings this Wed could be the shift. $SMMT $TERN $VKTX

1 · Reply

kubota2323 May. 2 at 2:45 AM

$TERN welp

0 · Reply

kingofking719 Apr. 30 at 6:07 PM

$UAMY $BULL $SOUN $TERN @JarvisProtocols we don't care

1 · Reply

55X_ROI_Q1_2026 Apr. 30 at 4:10 PM

$SLS SLS009 Pristine Safety Profile Durable Efficacy, for the most Dire of AML Mutations, worth more than $TERN and $FTSV You will wish you bought more. We All Will.

0 · Reply

55X_ROI_Q1_2026 Apr. 30 at 3:38 PM

$SLS $MRK $TERN

0 · Reply

55X_ROI_Q1_2026 Apr. 30 at 1:46 AM

$SLS $MRK $TERN Dr. Khan one of the Phase 2 clinicians, explains the ongoing pivotal randomized SLS PH2B AML-MR Expansion, Front line results, will be even better than the Prior P2B results in end stage setting. - this was before Harvard Prof, Dr. Amrein discovered a 3 fold More Potent dosing regime. - direct link below - worth a listen for those buying in now on the market tankage. . . . - BUY AND HOLD ALL THAT YOU CAN - your future you will thank you. Joshua F. Zeidner, MD — University of North Carolina, Lineberger Comprehensive Cancer Center (lead author) Omer Jamy — O'Neal Comprehensive Cancer Center, University of Alabama-Birmingham Bradley Christensen — Baylor Scott & White Research Institute Sharif Khan — Bon Secours Hematology & Oncology Dragan Cicic — SELLAS Life Sciences Group Tapan Kadia, MD — MD Anderson Cancer Center

0 · Reply

55X_ROI_Q1_2026 Apr. 29 at 10:56 PM

$SLS $MRK $TERN Just the Secondary Asset, SLS009 is worth at Least what GILD Paid for FTSV / $4.9B / $27 Per SLS Share - A Guaranteed 600% ROI - Should See 6 or 7 PR's in the Next 6 to7 months, including Final Randomized Pivotal Results and the AML-IMPACT EU PR in Q2.

0 · Reply

romanaround Apr. 29 at 10:12 PM

$ALT $BIOA $TERN $VKTX gosh dang my apologies to tern and bioa they are on top kings

0 · Reply

DonCorleone77 Apr. 29 at 7:54 PM

$TERN Attached is a Mizuho analyst note regarding TERN issued today.

0 · Reply

55X_ROI_Q1_2026 Apr. 29 at 7:21 PM

$SLS $GILD 20% of all AML Patients are AML-MR SLS009 Phase 2B Results in End Stage AML-MR Confirm SLS009 is RIGHT NOW worth More Than the $4.9B GILD Paid for FTSV - and the $7B $MRK paid for $TERN Just the Secondary Asset Guarantees SLS Investors at LEAST a 600% ROI - and a 5,000% + FREE ROLL when GPs Phase 3 Results are Announced. Could be any day.

0 · Reply

Market Cap	6.12B
Revenue (ttm)	0.00
Net Income (ttm)	-96.21M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	6,347,000
Avg Vol	6,722,514
Day's Range	N/A - N/A
Shares Out	115.52M
Stochastic %K	85%
Beta	-0.37
Analysts	Hold
Price Target	$53.00